FOOD AND FASTING PERIODS AS MEDICINE TO PREVENT DISEASE
Professor Leonie Heilbronn
University of Adelaide &
Group Leader Obesity and Metabolism,
South Australian Health and Medical Research Institute (SAHMRI)
Adelaide, South Australia
RESEARCHER PROFILE
Filmed in Adelaide, South Australia | February 2025
Professor Leonie Heilbronn is based at the South Australian Health and Medical Research Institute (SAHMRI), where she leads the Obesity and Metabolism laboratory. Her research is at the interface between basic and clinical science. She is internationally recognised for her work in nutritional modulation in humans and has made major contributions to our current understanding of mechanisms underlying conditions such as insulin resistance, particularly inflammation and lipid metabolism. She has also contributed significantly to current concepts of caloric restriction (CR), intermittent fasting (IF) and time restricted eating (TRE) in humans. She has published more than 110 peer reviewed papers in scientific journals and is an Associate Editor of Obesity, and Obesity Research and Clinical Practice.
Prof. Heilbronn is a translational investigator in obesity and diabetes research. She has a particular interest in understanding how fasting and meal timing alter nutrient signalling pathways to improve health and contributed extensively to current concepts in calorie restriction, intermittent fasting and time restricted eating. She has published more than 140 peer-reviewed manuscripts, and has a current h-index of 44. She is an Associate Editor of Obesity and the European Journal of Endocrinology. She is President of the Australia and New Zealand Obesity Society and an Associate Member of the Australian Academy of Health and Medical Science.
-
Novel therapy for pancreatic cancers, targeting molecular foundation
Dr Michael Lee is an experienced medical oncologist, sub-specialising in gastrointestinal cancers and neuroendocrine tumours at the Peter MacCallum Cancer Centre.
He plays a key role in molecular tumour boards at VCCC Alliance (Victorian Comprehensive Cancer Centre) and MPCCC (Monash Partners Comprehensive Cancer Consortium), ensuring the accurate and effective use of precision medicine in cancer care across the state.
-
Professor Matthew Kiernan
BRAIN AND MIND CENTRE
@ UNIVERSITY OF SYDNEY, NEW SOUTH WALES AUSTRALIA -
Identification & characterisation of molecular drivers of therapeutic resistance
Professor Pieter Eichhorn is an internationally experienced cancer biologist and research leader whose career has been defined by high-impact contributions at the interface of functional genomics, translational oncology, and research infrastructure strategy.
He completed his PhD at the University of Newcastle upon Tyne, contributing to the cloning of the gene associated with Cornelia de Lange Syndrome, before undertaking postdoctoral training at the Netherlands Cancer Institute in the laboratory of René Bernards. There, he performed pioneering functional genetic screens that identified key regulators of oncogenesis and therapy resistance, including critical roles for the PI3K signalling pathway in resistance to targeted breast cancer therapies.
